Rare diseases
Investigational molecules
Locations
474 conditions with trials, the busiest first
1 133 trials across Europe, recruiting first
Study of zolbetuximab combined with paclitaxel and ramucirumab for patients with previously treated CLDN18.
BelgiumStudy comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors
GermanyStudy of drug combination therapy for patients with lymph node-positive esophageal and esophagogastric junction cancer using carboplatin, paclitaxel, fluorouracil, folinic acid, docetaxel and oxaliplatin
The NetherlandsStudy of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer
FranceStudy of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis
CzechiaStudy of elexacaftor, tezacaftor and ivacaftor combination therapy to evaluate blood levels in patients with Cystic Fibrosis
ItalyStudy of adipose-derived mesenchymal stem cell injections to treat mouth fibrosis in patients with systemic scleroderma
FranceStudy of carboplatin, paclitaxel, and tislelizumab treatment in patients with resectable locally advanced oral cavity squamous cell carcinoma
ItalyStudy of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer
FinlandA study of Pseudovax, molgramostim and tislelizumab combination therapy for patients with pseudomyxoma peritonei cancer
NorwayStudy of rilvegostomig, trastuzumab deruxtecan, and AZD0901 in patients with locally advanced resectable gastroesophageal cancer before and after surgery
ItalyComparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas
FranceThe therapies tested most often in Gastrointestinal disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
